Abstract：Enterovirus 71 (EV71) is a major causative factor of hand, foot and mouth disease (HFMD). Currently, the mechanism of HFMD is not clearly understood, and neither vaccine nor antiviral therapy is available. As a capsid protein of EV71, VP1 plays an important role during the adsorption and penetration of EV71. The presence of the VP1-specific neutralizing epitopes makes it an important position in the EV71 vaccine research. This review article provides a summary of the structure, function and associated vaccine of EV71 VP1.
[1] Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study[J]. Lancet Infect Dis, 2014, 14(4): 308-318. doi:10.1016/S1473-3099(13)70342-6 [2] Plevka P, Perera R, Cardosa J, et al. Crystal structure of human enterovirus 71[J]. Science, 2012, 336(6086): 1274-1274. doi:10.1126/science.1218713 [3] Wang X, Peng W, Ren J, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71[J]. Nat Struct Mol Biol, 2012, 19(4): 424-429. doi:10.1038/nsmb.2255 [4] Ke YY, Chen YC, Lin TH. Structure of the virus capsid protein VP1 of enterovirus 71 predicted by some homology modeling and molecular docking studies[J]. J Computat Chem, 2006, 27(13): 1556-1570. doi:10.1002/Jcc.20460 [5] Miyamura K, Nishimura Y, Abo M, et al. Adaptive mutations in the genomes of enterovirus 71 strains following infection of mouse cells expressing human P-selectin glycoprotein ligand-1[J]. J General Virol, 2011, 92(2): 287-291. [6] Chen P, Song ZL, Qi YH, et al. Molecular determinants of enterovirus 71 viral entry cleft around gln-172 on vp1 protein interacts with variable region on scavenge receptor b 2[J]. J Biologic Chem, 2012, 287(9): 6406-6420. doi:10.1074/jbc.M111.301622 [7] Yamayoshi S, Yamashita Y, Li JF, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71[J]. Nat Med, 2009, 15(7): 798-801. doi:10.1038/nm.1992.Epub 2009 Jun 21. [8] Nishimura Y, Shimojima M, Tano Y, et al. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71[J]. Nat Med, 2009, 15(7): 794-797. doi:10.1038/nm.1961.Epub 2009 Jun 21. [9] Yang B, Chuang H, Yang KD. Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells[J]. Virol J, 2009, 6(141): 1-6. doi:10.1186/1743-422x-6-141 [10] Yang SL, Chou YT, Wu CN, et al. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity[J]. J Virol, 2011, 85(22): 11809-11820. doi:10.1128/JVI.00297-11 [11] Nishimura Y, Lee H, Hafenstein S, et al. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction[J]. PLoS Pathogens, 2013, 9(7): e1003511-e1003511. doi:10.1371/journal.ppat.1003511 [12] Tan CW, Poh CL, Sam IC, et al. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor[J]. J Virol, 2013, 87(1): 611-620. doi:10.1128/JVI.02226-12 [13] Lal SK, Kumar P, Yeo WM, et al. The VP1 protein of human enterovirus 71 self-associates via an interaction domain spanning amino acids 66-297[J]. J Med Virol, 2006, 78(5): 582-590. doi:10.1002/Jmv.20579 [14] Haolong C, Du N, Hongchao T, et al. Enterovirus 71 VP1 activates calmodulin-dependent protein kinase II and results in the rearrangement of vimentin in human astrocyte cells[J]. PLoS One, 2013, 8(9): e73900-e73900. doi:10.1371/journal.pone.0073900 [15] Weng TY, Chen LC, Shyu HW, et al. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells[J]. Antiviral Res, 2005, 67(1): 31-37. doi:10.1016/j.antiviral.2005.03.005 [16] Cifuente JO, Lee H, Yoder JD, et al. Structures of the procapsid and mature virion of Enterovirus 71 strain 1095[J]. J Virol, 2013, 87(13): 7637-7645. doi:10.1128/Jvi.03519-12 [17] Cao YG, Li ZH, Yue YY, et al. Construction and evaluation of a novel Bacillus subtilis spores-based enterovirus 71 vaccine[J]. J Appl Biomed, 2013, 11(2): 105-113. doi:10.2478/v10136-012-0032-9 [18] Chen HL, Huang JY, Chu TW, et al. Expression of VP1 protein in the milk of transgenic mice: A potential oral vaccine protects against enterovirus 71 infection[J]. Vaccine, 2008, 26(23): 2882-2889. doi:10.1016/j.vaccine.2008.03.041 [19] Kiener TK, Premanand B, Kwang J. Immune responses to baculovirus-displayed enterovirus 71 VP1 antigen[J]. Expert Rev Vaccines, 2013, 12(4): 357-364. doi:10.1586/Erv.13.18 [20] Meng T, Kolpe AB, Kiener TK, et al. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human Enterovirus 71 strains in mice[J]. PLoS One, 2011, 6(7): e21757-e21757. doi:10.1371/journal.pone.0021757 [21] Sivasamugham LA, Cardosa MJ, Tan WS, et al. Recombinant Newcastle disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits[J]. J Med Virol, 2006, 78(8): 1096-1104. doi:10.1002/Jmv.20668 [22] Guang D, Foo W, Alonso S, et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides[J]. Virus Res, 2007, 125(1): 61-68. doi:10.1016/j.virusres.2006.12.005 [23] Lim XF, Jia Q, Chow VTK, et al. Characterization of a novel monoclonal antibody reactive against the N-terminal region of Enterovirus 71 VP1 capsid protein[J]. J Virologic Methods, 2013, 188(1-2): 76-82. doi:10.1016/j.jviromet.2012.11.038 [24] Lim XF, Jia Q, Khong WX, et al. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection[J]. PLoS One, 2012, 7(1): e29751. [25] Chen HF, Chang MH, Chiang BL, et al. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71[J]. Vaccine, 2006, 24(15): 2944-2951. doi:10.1016/j.vaccine.2005.12.047 [26] Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China[J]. N Engl J Med, 2014, 370(9): 818-828. [27] Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children[J]. N Engl J Med, 2014, 370(9): 829-837. doi:10.1056/NEJMoa1303224
2015, Vol. 31 
